Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease

The greater omentum is frequently involved in the course of gastrointestinal and ovarian tumors. Therefore, common practice in surgical treatment for especially gastric and ovarian cancer includes removal of the greater omentum. Paradoxically, many immune cells, such as macrophages that accumulate i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology, Immunotherapy Immunotherapy, 2006-09, Vol.55 (9), p.1043-1051
Hauptverfasser: OOSTERLING, S. J, VAN DER BIJ, G. J, BÖGELS, M, VAN DER SIJP, J. R. M, BEELEN, R. H. J, MEIJER, S, VAN EGMOND, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1051
container_issue 9
container_start_page 1043
container_title Cancer Immunology, Immunotherapy
container_volume 55
creator OOSTERLING, S. J
VAN DER BIJ, G. J
BÖGELS, M
VAN DER SIJP, J. R. M
BEELEN, R. H. J
MEIJER, S
VAN EGMOND, M
description The greater omentum is frequently involved in the course of gastrointestinal and ovarian tumors. Therefore, common practice in surgical treatment for especially gastric and ovarian cancer includes removal of the greater omentum. Paradoxically, many immune cells, such as macrophages that accumulate in so-called milky spots, reside within the omentum and are cytotoxic against tumor cells ex vivo. Consequently, omental macrophages might play an important role in killing tumor cells, and may hereby prevent development into local peritoneal recurrences. In the present study, we therefore evaluated the role of the omentum and the clinical relevance of omentectomy in minimal residual disease (MRD). Tumor cell dissemination patterns on the omentum in a rat model were examined using DiI-labelled CC531s tumor cells. Additionally, intra peritoneal (i.p.) tumor load was investigated in rats that underwent omentectomy or sham laparotomy followed by i.p. injection of CC531s cells on day 21, which represented MRD. At 4 h post injection, tumor cells predominantly adhered on milky spots. Number of cells thereafter declined rapidly suggesting initial tumor killing functions in these specific immune aggregates. Despite initial reduction observed in milky spots, numbers of tumor cells however increased at fatty tissue stripes that border the omentum. This indicated proliferation at these locations, which corresponded to macroscopic observations of the omenta on day 21 after tumor cell injection. Omentectomy resulted in reduced intra-abdominal tumor load, which was completely attributable to the absence of the omentum, as tumor development did not differ on other sites. Even in the MRD group microscopic clusters of tumor cells located in the omentum eventually developed into macroscopic nodules. Since the ability of omental milky spots is, even in MRD, insufficient to prevent intra abdominal tumor outgrowth, omentectomy, which reduces tumor load, is recommended in surgical treatment of intra abdominal tumors that are prone to disseminate intraperitoneally.
doi_str_mv 10.1007/s00262-005-0101-y
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11030682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68002717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-2f08f8098d2e005d08ca91c7452a2ecf39d9f15ebf87d57460c6f3a02d94a0bc3</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0EotvCD-CCLCS4pczY-bBPCFVQKlXqpZwtr2O3LkkcbKcoV345XnZFoRdOHo2feeeTkFcIpwjQvU8ArGUVQFMBAlbrE7LBmhePaPAp2QCvoeoA6iNynNJdMRhI-ZwcYcsRO8425OfFlBbnvPF2ylRv_eDzSoOjYSwOPdDRD99WmuaQE82BztHe78jZRp_DZAuRlzFEGpZ8E8OPfEvTMs8hFvy3hDU5jCv1U1Ga_Fj4aJPvl2L0Plmd7AvyzOkh2ZeH94R8_fzp-uxLdXl1fnH28bIyDchcMQfCCZCiZ7Z03IMwWqLp6oZpZo3jspcOG7t1ouubrm7BtI5rYL2sNWwNPyEf9rrzsh1tb0pxUQ9qjqWquKqgvfr3Z_K36ibcK0Tg0ApWFN4dFGL4vtiU1eiTscOgJxuWpFpRFtKVwf4PRMlbxFoU8M0j8C4scSpjUAx5Ax3IXVrcQyaGlKJ1f2pGULtDUPtDUGUsancIai0xr_9u9iHisPkCvD0AOhk9uKgn49MD14mmbkXNfwEA7b_a</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213507092</pqid></control><display><type>article</type><title>Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>OOSTERLING, S. J ; VAN DER BIJ, G. J ; BÖGELS, M ; VAN DER SIJP, J. R. M ; BEELEN, R. H. J ; MEIJER, S ; VAN EGMOND, M</creator><creatorcontrib>OOSTERLING, S. J ; VAN DER BIJ, G. J ; BÖGELS, M ; VAN DER SIJP, J. R. M ; BEELEN, R. H. J ; MEIJER, S ; VAN EGMOND, M</creatorcontrib><description>The greater omentum is frequently involved in the course of gastrointestinal and ovarian tumors. Therefore, common practice in surgical treatment for especially gastric and ovarian cancer includes removal of the greater omentum. Paradoxically, many immune cells, such as macrophages that accumulate in so-called milky spots, reside within the omentum and are cytotoxic against tumor cells ex vivo. Consequently, omental macrophages might play an important role in killing tumor cells, and may hereby prevent development into local peritoneal recurrences. In the present study, we therefore evaluated the role of the omentum and the clinical relevance of omentectomy in minimal residual disease (MRD). Tumor cell dissemination patterns on the omentum in a rat model were examined using DiI-labelled CC531s tumor cells. Additionally, intra peritoneal (i.p.) tumor load was investigated in rats that underwent omentectomy or sham laparotomy followed by i.p. injection of CC531s cells on day 21, which represented MRD. At 4 h post injection, tumor cells predominantly adhered on milky spots. Number of cells thereafter declined rapidly suggesting initial tumor killing functions in these specific immune aggregates. Despite initial reduction observed in milky spots, numbers of tumor cells however increased at fatty tissue stripes that border the omentum. This indicated proliferation at these locations, which corresponded to macroscopic observations of the omenta on day 21 after tumor cell injection. Omentectomy resulted in reduced intra-abdominal tumor load, which was completely attributable to the absence of the omentum, as tumor development did not differ on other sites. Even in the MRD group microscopic clusters of tumor cells located in the omentum eventually developed into macroscopic nodules. Since the ability of omental milky spots is, even in MRD, insufficient to prevent intra abdominal tumor outgrowth, omentectomy, which reduces tumor load, is recommended in surgical treatment of intra abdominal tumors that are prone to disseminate intraperitoneally.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-005-0101-y</identifier><identifier>PMID: 16311732</identifier><identifier>CODEN: CIIMDN</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Abdomen ; Adenocarcinoma - immunology ; Adenocarcinoma - prevention &amp; control ; Adenocarcinoma - secondary ; Adipose Tissue - pathology ; Animals ; Antineoplastic agents ; Biological and medical sciences ; Cell Adhesion - immunology ; Cell Line, Tumor ; Cell Proliferation ; Colonic Neoplasms - immunology ; Colonic Neoplasms - prevention &amp; control ; Colonic Neoplasms - secondary ; Digestive System Surgical Procedures ; Disease Models, Animal ; Immunotherapy ; Lymphoid Tissue - pathology ; Macrophages - immunology ; Male ; Medical sciences ; Neoplasm Transplantation ; Neoplasm, Residual ; Omentum - immunology ; Omentum - pathology ; Omentum - surgery ; Original ; Ovarian cancer ; Peritoneal Neoplasms - immunology ; Peritoneal Neoplasms - prevention &amp; control ; Peritoneal Neoplasms - secondary ; Pharmacology. Drug treatments ; Rats ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2006-09, Vol.55 (9), p.1043-1051</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer-Verlag 2006</rights><rights>Springer-Verlag 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-2f08f8098d2e005d08ca91c7452a2ecf39d9f15ebf87d57460c6f3a02d94a0bc3</citedby><cites>FETCH-LOGICAL-c509t-2f08f8098d2e005d08ca91c7452a2ecf39d9f15ebf87d57460c6f3a02d94a0bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030682/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030682/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17854684$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16311732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OOSTERLING, S. J</creatorcontrib><creatorcontrib>VAN DER BIJ, G. J</creatorcontrib><creatorcontrib>BÖGELS, M</creatorcontrib><creatorcontrib>VAN DER SIJP, J. R. M</creatorcontrib><creatorcontrib>BEELEN, R. H. J</creatorcontrib><creatorcontrib>MEIJER, S</creatorcontrib><creatorcontrib>VAN EGMOND, M</creatorcontrib><title>Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><description>The greater omentum is frequently involved in the course of gastrointestinal and ovarian tumors. Therefore, common practice in surgical treatment for especially gastric and ovarian cancer includes removal of the greater omentum. Paradoxically, many immune cells, such as macrophages that accumulate in so-called milky spots, reside within the omentum and are cytotoxic against tumor cells ex vivo. Consequently, omental macrophages might play an important role in killing tumor cells, and may hereby prevent development into local peritoneal recurrences. In the present study, we therefore evaluated the role of the omentum and the clinical relevance of omentectomy in minimal residual disease (MRD). Tumor cell dissemination patterns on the omentum in a rat model were examined using DiI-labelled CC531s tumor cells. Additionally, intra peritoneal (i.p.) tumor load was investigated in rats that underwent omentectomy or sham laparotomy followed by i.p. injection of CC531s cells on day 21, which represented MRD. At 4 h post injection, tumor cells predominantly adhered on milky spots. Number of cells thereafter declined rapidly suggesting initial tumor killing functions in these specific immune aggregates. Despite initial reduction observed in milky spots, numbers of tumor cells however increased at fatty tissue stripes that border the omentum. This indicated proliferation at these locations, which corresponded to macroscopic observations of the omenta on day 21 after tumor cell injection. Omentectomy resulted in reduced intra-abdominal tumor load, which was completely attributable to the absence of the omentum, as tumor development did not differ on other sites. Even in the MRD group microscopic clusters of tumor cells located in the omentum eventually developed into macroscopic nodules. Since the ability of omental milky spots is, even in MRD, insufficient to prevent intra abdominal tumor outgrowth, omentectomy, which reduces tumor load, is recommended in surgical treatment of intra abdominal tumors that are prone to disseminate intraperitoneally.</description><subject>Abdomen</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - prevention &amp; control</subject><subject>Adenocarcinoma - secondary</subject><subject>Adipose Tissue - pathology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Adhesion - immunology</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Colonic Neoplasms - immunology</subject><subject>Colonic Neoplasms - prevention &amp; control</subject><subject>Colonic Neoplasms - secondary</subject><subject>Digestive System Surgical Procedures</subject><subject>Disease Models, Animal</subject><subject>Immunotherapy</subject><subject>Lymphoid Tissue - pathology</subject><subject>Macrophages - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Transplantation</subject><subject>Neoplasm, Residual</subject><subject>Omentum - immunology</subject><subject>Omentum - pathology</subject><subject>Omentum - surgery</subject><subject>Original</subject><subject>Ovarian cancer</subject><subject>Peritoneal Neoplasms - immunology</subject><subject>Peritoneal Neoplasms - prevention &amp; control</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkk1v1DAQhi0EotvCD-CCLCS4pczY-bBPCFVQKlXqpZwtr2O3LkkcbKcoV345XnZFoRdOHo2feeeTkFcIpwjQvU8ArGUVQFMBAlbrE7LBmhePaPAp2QCvoeoA6iNynNJdMRhI-ZwcYcsRO8425OfFlBbnvPF2ylRv_eDzSoOjYSwOPdDRD99WmuaQE82BztHe78jZRp_DZAuRlzFEGpZ8E8OPfEvTMs8hFvy3hDU5jCv1U1Ga_Fj4aJPvl2L0Plmd7AvyzOkh2ZeH94R8_fzp-uxLdXl1fnH28bIyDchcMQfCCZCiZ7Z03IMwWqLp6oZpZo3jspcOG7t1ouubrm7BtI5rYL2sNWwNPyEf9rrzsh1tb0pxUQ9qjqWquKqgvfr3Z_K36ibcK0Tg0ApWFN4dFGL4vtiU1eiTscOgJxuWpFpRFtKVwf4PRMlbxFoU8M0j8C4scSpjUAx5Ax3IXVrcQyaGlKJ1f2pGULtDUPtDUGUsancIai0xr_9u9iHisPkCvD0AOhk9uKgn49MD14mmbkXNfwEA7b_a</recordid><startdate>20060901</startdate><enddate>20060901</enddate><creator>OOSTERLING, S. J</creator><creator>VAN DER BIJ, G. J</creator><creator>BÖGELS, M</creator><creator>VAN DER SIJP, J. R. M</creator><creator>BEELEN, R. H. J</creator><creator>MEIJER, S</creator><creator>VAN EGMOND, M</creator><general>Springer</general><general>Springer Nature B.V</general><general>Springer-Verlag</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20060901</creationdate><title>Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease</title><author>OOSTERLING, S. J ; VAN DER BIJ, G. J ; BÖGELS, M ; VAN DER SIJP, J. R. M ; BEELEN, R. H. J ; MEIJER, S ; VAN EGMOND, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-2f08f8098d2e005d08ca91c7452a2ecf39d9f15ebf87d57460c6f3a02d94a0bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Abdomen</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - prevention &amp; control</topic><topic>Adenocarcinoma - secondary</topic><topic>Adipose Tissue - pathology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Adhesion - immunology</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Colonic Neoplasms - immunology</topic><topic>Colonic Neoplasms - prevention &amp; control</topic><topic>Colonic Neoplasms - secondary</topic><topic>Digestive System Surgical Procedures</topic><topic>Disease Models, Animal</topic><topic>Immunotherapy</topic><topic>Lymphoid Tissue - pathology</topic><topic>Macrophages - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Transplantation</topic><topic>Neoplasm, Residual</topic><topic>Omentum - immunology</topic><topic>Omentum - pathology</topic><topic>Omentum - surgery</topic><topic>Original</topic><topic>Ovarian cancer</topic><topic>Peritoneal Neoplasms - immunology</topic><topic>Peritoneal Neoplasms - prevention &amp; control</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OOSTERLING, S. J</creatorcontrib><creatorcontrib>VAN DER BIJ, G. J</creatorcontrib><creatorcontrib>BÖGELS, M</creatorcontrib><creatorcontrib>VAN DER SIJP, J. R. M</creatorcontrib><creatorcontrib>BEELEN, R. H. J</creatorcontrib><creatorcontrib>MEIJER, S</creatorcontrib><creatorcontrib>VAN EGMOND, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OOSTERLING, S. J</au><au>VAN DER BIJ, G. J</au><au>BÖGELS, M</au><au>VAN DER SIJP, J. R. M</au><au>BEELEN, R. H. J</au><au>MEIJER, S</au><au>VAN EGMOND, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><addtitle>Cancer Immunol Immunother</addtitle><date>2006-09-01</date><risdate>2006</risdate><volume>55</volume><issue>9</issue><spage>1043</spage><epage>1051</epage><pages>1043-1051</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><coden>CIIMDN</coden><abstract>The greater omentum is frequently involved in the course of gastrointestinal and ovarian tumors. Therefore, common practice in surgical treatment for especially gastric and ovarian cancer includes removal of the greater omentum. Paradoxically, many immune cells, such as macrophages that accumulate in so-called milky spots, reside within the omentum and are cytotoxic against tumor cells ex vivo. Consequently, omental macrophages might play an important role in killing tumor cells, and may hereby prevent development into local peritoneal recurrences. In the present study, we therefore evaluated the role of the omentum and the clinical relevance of omentectomy in minimal residual disease (MRD). Tumor cell dissemination patterns on the omentum in a rat model were examined using DiI-labelled CC531s tumor cells. Additionally, intra peritoneal (i.p.) tumor load was investigated in rats that underwent omentectomy or sham laparotomy followed by i.p. injection of CC531s cells on day 21, which represented MRD. At 4 h post injection, tumor cells predominantly adhered on milky spots. Number of cells thereafter declined rapidly suggesting initial tumor killing functions in these specific immune aggregates. Despite initial reduction observed in milky spots, numbers of tumor cells however increased at fatty tissue stripes that border the omentum. This indicated proliferation at these locations, which corresponded to macroscopic observations of the omenta on day 21 after tumor cell injection. Omentectomy resulted in reduced intra-abdominal tumor load, which was completely attributable to the absence of the omentum, as tumor development did not differ on other sites. Even in the MRD group microscopic clusters of tumor cells located in the omentum eventually developed into macroscopic nodules. Since the ability of omental milky spots is, even in MRD, insufficient to prevent intra abdominal tumor outgrowth, omentectomy, which reduces tumor load, is recommended in surgical treatment of intra abdominal tumors that are prone to disseminate intraperitoneally.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>16311732</pmid><doi>10.1007/s00262-005-0101-y</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology, Immunotherapy, 2006-09, Vol.55 (9), p.1043-1051
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11030682
source MEDLINE; Springer Nature - Complete Springer Journals; PubMed Central
subjects Abdomen
Adenocarcinoma - immunology
Adenocarcinoma - prevention & control
Adenocarcinoma - secondary
Adipose Tissue - pathology
Animals
Antineoplastic agents
Biological and medical sciences
Cell Adhesion - immunology
Cell Line, Tumor
Cell Proliferation
Colonic Neoplasms - immunology
Colonic Neoplasms - prevention & control
Colonic Neoplasms - secondary
Digestive System Surgical Procedures
Disease Models, Animal
Immunotherapy
Lymphoid Tissue - pathology
Macrophages - immunology
Male
Medical sciences
Neoplasm Transplantation
Neoplasm, Residual
Omentum - immunology
Omentum - pathology
Omentum - surgery
Original
Ovarian cancer
Peritoneal Neoplasms - immunology
Peritoneal Neoplasms - prevention & control
Peritoneal Neoplasms - secondary
Pharmacology. Drug treatments
Rats
Tumors
title Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A44%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insufficient%20ability%20of%20omental%20milky%20spots%20to%20prevent%20peritoneal%20tumor%20outgrowth%20supports%20omentectomy%20in%20minimal%20residual%20disease&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=OOSTERLING,%20S.%20J&rft.date=2006-09-01&rft.volume=55&rft.issue=9&rft.spage=1043&rft.epage=1051&rft.pages=1043-1051&rft.issn=0340-7004&rft.eissn=1432-0851&rft.coden=CIIMDN&rft_id=info:doi/10.1007/s00262-005-0101-y&rft_dat=%3Cproquest_pubme%3E68002717%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213507092&rft_id=info:pmid/16311732&rfr_iscdi=true